OwlBrief delivers the latest global news and insights in a concise, easy-to-read format. Stay informed with wise, reliable updates tailored for you. Discover the world’s top stories at a glance.
India is gradually reducing its dependency on China for pharmaceutical raw materials, known as active pharmaceutical ingredients (APIs). The country has taken initiatives to boost domestic production and diversify its sources to enhance self-reliance in the pharmaceutical sector.
Key Insights:
India's Pharmaceutical Sector Dependency: India has historically relied heavily on China for APIs due to cost-effectiveness and lack of domestic production capacity. This dependency poses risks to supply chain stability, especially during geopolitical tensions.
Government Initiatives for Self-Reliance: The Indian government has launched various schemes to encourage domestic manufacturing of APIs. These include financial incentives and support for infrastructure development in the pharmaceutical sector.
Challenges in Reducing Dependency: Despite initiatives, India faces challenges such as high production costs and the need for technological advancements to match China's production capabilities. Transitioning will require significant investment and time.
